Asia-Pacific Bladder Cancer Therapeutics Market estimated to grow wit Asia-Pacific Bladder Cancer Therapeutics Market es | Page 2

The Asia-Pacific “Bladder Cancer Therapeutics Market” research report, published by
Market Data Forecast estimates that the market itself was worth $80.8 million in 2016 and
expected to grow at a CAGR of 5.68%, to reach $106.6 million by 2021.
The bladder is a hollow organ in the lower part of the abdomen that stores urine until it is
passed out of the body.
The most common type of bladder cancer is transitional cell carcinoma, which begins in
urothelial cells that line the inside of the bladder. Urothelial cells are transitional cells, which
are able to change shape and stretch when the bladder is full. This type of cancer is also
called urothelial carcinoma. Other types of bladder cancer include squamous cell carcinoma
(cancer that begins in thin, flat cells lining the bladder) and adenocarcinoma (cancer that
begins in cells that make and release mucus and other fluids).
Request Free Sample: http://www.marketdataforecast.com/market-reports/asia-pacific-
bladder-cancer-therapeutics-market-1152/request-sample
People who smoke have an increased risk of bladder cancer. Being exposed to certain
chemicals and having chronic bladder infections can also increase the risk of bladder cancer.
The most common sign of bladder cancer is blood in the urine. Bladder cancer is often
diagnosed at an early stage, when the cancer is easier to treat.
The report also presents detailed analysis of multitude of factors affecting the Bladder
Cancer Therapeutics market bearing either positive or negative outcomes. Some of those
factors are:






Rising healthcare expenditure
Increasing cancer patient population
Growing involvement of universities & research institutes
Rising focus of foreign pharmaceutical companies on Asian market
Unawareness among bladder cancer patients about advanced cancer therapies
Presence of more number of generic bladder cancer therapeutics
For granular level understanding the Bladder Cancer Therapeutics Market is segmented
based on product and application, each being provided with Market Size Estimates and Y-o-
Y Forecasts. Asia-Pacific Bladder Cancer Therapeutics market is segmented based on type
and treatment. Based on type, the market is further sub-segmented as Transitional Cell
Bladder Cancer, Non Muscle Invasive/Superficial Bladder Cancer, Invasive Bladder Cancer,
Squamous Cell Bladder Cancer, Adenocarcinoma of the Bladder, and Rare Bladder Cancers.
Based on treatment, the market is further segmented as Surgery, Chemotherapy,
Immunotherapy, Radiation Therapy, and Intravesical Therapy.
The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea,
and Australia. The Asia-Pacific region is projected to grow at the highest CAGR during the